DOI: 10.12890/2026_006649

Semaglutide-induced ischemic colitis in a middle-aged female without vascular risk factors

Authors

  • Marwan Joma Department of Internal Medicine, University of Toledo Medical Center, Toledo, USA
  • Abdulrahman M. Karam Department of Internal Medicine, University of Toledo Medical Center, Toledo, USA
  • Wasef Sayeh Department of Gastroenterology and Hepatology, University of Toledo Medical Center, Toledo, USA
  • Bisher Sawaf Department of Internal Medicine, University of Toledo Medical Center, Toledo, USA
  • Anan Bseiso Department of Pathology, University of Toledo Medical Center, Toledo, USA
  • Ajay Katwala College of Health Sciences, Marquette University, Milwaukee, USA
  • Yaseen Alastal Department of Gastroenterology and Hepatology, University of Toledo Medical Center, Toledo, USA

abdulrahman.karam@outlook.com

Keywords

Ischemic colitis, semaglutide, vascular risk factors, cessation of therapy

Abstract

Ischemic colitis (IC) typically occurs in patients with vascular risk factors. We report a case of a 53-year-old woman without comorbidities who developed IC after initiating semaglutide. She presented with acute abdominal pain and haematochezia. Imaging, colonoscopy, and biopsy confirmed IC, while infectious workup was negative. Symptoms resolved following discontinuation of semaglutide and supportive care. This case highlights a potential association between glucagon-like peptide-1 receptor agonists and IC and underscores the importance of recognizing rare adverse effects in patients without traditional risk factors.

View the entire article

Downloads

References

  1. Brandt LJ, Feuerstadt P, Longstreth GF, Boley SJ; American College of Gastroenterology. ACG clinical guideline: epidemiology, risk factors, patterns of presentation, diagnosis, and management of colon ischemia (CI). Am J Gastroenterol 2015;110:18-44. doi: 10.1038/ajg.2014.395
  2. Cappell MS. Intestinal (mesenteric) vasculopathy. II. Ischemic colitis and chronic mesenteric ischemia. Gastroenterol Clin North Am 1998;27:827-60. doi: 10.1016/s0889-8553(05)70034-0
  3. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 2021;46:101102. doi: 10.1016/j.molmet.2020.101102
  4. Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab 2022;24:94-105. doi: 10.1111/dom.14551
  5. Bayless D, Singh J, Park BU, Sweetser S. Tirzepatide-Associated Colonic Ischemia. ACG Case Rep J 2024;11:e01551. doi: 10.14309/crj.0000000000001551
  6. Wichelmann TA, Kruchko DH, Silas D. Glucagon-like peptide-1 receptor agonist-associated colonic ischemia: a case report. Am J Gastroenterol 2022;117:e1424. doi: 10.14309/01.ajg.0000864992.88559.a6
  7. Sekhon S, Bacon J, Kahlon IS. Semaglutide-Associated Ischemic Colitis in a Patient Without Traditional Risk Factors: A Case Report. Cureus 2025;17:e78832. doi: 10.7759/cureus.78832
  8. Mayer N, Sutherland M, Muralidharan S, Patel D. Emerging gastrointestinal risks of GLP-1 receptor agonists: a case of ischemic colitis in a young woman on semaglutide. Am J Gastroenterol 2025;120:S832. doi: 10.14309/01.ajg.0001142992.25452.9d

Published

2026-07-10

Issue

Vol. 13 No. 7 (2026)

Categories

How to Cite

1.
Joma M, Karam AM, Sayeh W, Sawaf B, Bseiso A, Katwala A, et al. Semaglutide-induced ischemic colitis in a middle-aged female without vascular risk factors. EJCRIM [Internet]. 2026 Jul. 10 [cited 2026 Nov. 3];13(7). Available from: https://ejcrim.com/index.php/ejcrim/article/view/6649

Most read articles by the same author(s)